Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK Plc)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: July 2011 (Notification date: July 11, 2011)
Context: This filing serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding share plan transactions rather than a financial results report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details an administrative increase in notional share interests for specific individuals following a dividend reinvestment.
Management Commentary and Unusual Items
Transaction Details:
- Event: Re-investment of the dividend paid to shareholders on July 7, 2011.
- Price: 1365.75 pence per share.
- Participants: Mr E J Gray, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Regulatory Basis: Notification made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the dividend payment date of July 7, 2011, and the corresponding reinvestment price of 1365.75 pence.
- Confirm the specific notional share increases for the named directors and managers listed in the filing.
- Review the company's broader financial results for the period ending July 2011 in separate filings (e.g., Form 20-F or interim reports) as this 6-K contains no financial performance data.